RHS wins HWA Lab competition
Oct 13, 2017 -
RHS takes out first prize in the inaugural HWA Lab competition
Provides RHS with additional funding to advance software development to accompany DOPlify™
RHS presenting at key National and International reproductive medicine meetings
Adelaide, 12 October 2017: RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that the Company has been awarded first prize in the inaugural HWA Lab pitching competition.
The inaugural Hybrid World Adelaide (“HWA”) conference was held on 4-5 October bringing together digital experts across space, biotech, gaming, automation, robotics, blockchain, cybersecurity, agritech and artificial intelligence. The conference was followed by the HWA Lab program designed to identify and fund the next generation of applied digital technologies. The opportunity to pitch was open to South Australian, interstate and overseas companies and RHS was awarded the first prize of $25,000 from the total prize pool of $85,000 funded through TechInSA.
RHS was one of 15 companies selected to pitch for the grant funding aimed at bringing new projects, products or concepts using digital technologies to solve real world problems. RHS will use these funds to develop improvements in Next Generation Sequencing data analysis that are particularly suited to the Company’s own DOPlify™ Whole Genome Amplification kit. Applications include genetic profiling of circulating tumour cells, which will assist in characterising the cause and location of the primary tumour to potentially further personalised medical treatments. In addition, non-invasive combined Pre-implantation Genetic Screening and Diagnosis of IVF embryos using spent embryo culture medium will be assisted. Being connected to GigCity and now having access to funding for software improvements positions RHS to use its experience and expertise to advance single cell applications using its world class DOPlify™ kit.